Vericel Corp
Vericel Corp (VCEL): 4 pipeline candidates · 5 upcoming catalysts · ~9 mo cash runway · 1 clinical trial. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
9.1 months
D/E 0.36 · 0% dilution
Lead: Approved
4 candidates
5 upcoming, next in ~481d
0 buys · 15 sells (180d)
A transparent, data-derived signal for Vericel Corpacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$2.0B
Cash
$109.3M
Quarterly Burn
$57.3M
Runway
9.1 mo
Revenue
$68.4M
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (4 candidates)
| Drug | Phase |
|---|---|
| Epicel | Approved |
| MACI | Phase 3 |
| MACI Ankle | Phase 3 |
| NexoBrid | Approved |
Upcoming Catalysts (5)
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
277
Total value held
$1.71B
| Holder | Shares | Value |
|---|---|---|
| blackrock, inc. | 7,765,344 | $249.8M |
| vanguard capital management llc | 4,461,512 | $143.5M |
| state street corp | 3,152,130 | $101.4M |
| sg capital management llc | 1,959,287 | $63.0M |
| william blair investment management, llc | 1,832,709 | $59.0M |
| bnp paribas asset management holding s.a. | 1,723,572 | $55.4M |
| geneva capital management llc | 1,646,818 | $53.0M |
| congress asset management co | 1,506,918 | $48.5M |
| geode capital management, llc | 1,254,862 | $40.4M |
| susquehanna international group, llp | 1,172,800 | $37.7M |
Showing top 10 of 277 institutional holders of Vericel Corp. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Vericel Corp's pipeline?
Vericel Corp (VCEL) has 4 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Vericel Corp's lead drug candidate?
Vericel Corp's most advanced tracked candidate is Epicel (Approved) for Deep-dermal or full-thickness burns comprising greater than or equal to 30 percent of a patient's total body surface area.
What is Vericel Corp's next catalyst?
Vericel Corp's next tracked catalyst is a Patent_Expiry event — "Patent/Exclusivity Expiry: MACRILEN" — expected October 12, 2027.
What is Vericel Corp's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Vericel Corp has approximately 9.1 months of cash runway.
What is Vericel Corp's market capitalization?
Vericel Corp's market capitalization is approximately $2.0B.
Get the full picture on Vericel Corp
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.